Inc., Walkersville, MD, USA) were maintained in SmBM medium supplemented with 5%
fetal bovine serum, 0.5 ng/ml human epidermal growth factor (hEGF), 5 µg/ml
insulin, 2 ng/ml human fibroblast growth factor-basic (hFGF-b), 50 µg/ml
gentamicin and 50 ng/ml amphotericin B. Cells were maintained at 37 °C in a
humidified atmosphere (5% CO2), fed every 48–72 h, and passaged when
cells reached 90–95% confluence. Then the hBSMCs (passages 4–7) were seeded in
6-well plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA) at density of
3,500 cells/cm2 and, when 80–85% confluence was observed, cells were
cultured without serum for 24 h before the addition of PGD2. At the
indicated time after the treatment with PGD2, hBSMCs were immediately
collected and disrupted with 1× SDS sample buffer (150 µl/well), and used for
Western blot analyses.